Cryoport Inc (NASDAQ: CYRX) is a life sciences supply chain company that provides temperature-controlled logistics, biostorage, bioservices, and cryogenic equipment for biological materials, with a primary focus on cell and gene therapy (CGT) products. Revenue comes from two reportable segments: Life Sciences Services, which covers temperature-controlled logistics, biostorage, and bioservices sold directly to biopharmaceutical clients, and Life Sciences Products, which manufactures and sells cryogenic freezers, dewars, and transport systems through direct sales and a distribution network. The company operates across three business units: Cryoport Systems (BioLogistics, BioServices, cryopreservation), CryoGene (long-term biostorage for preclinical and early-stage clinical programs), and MVE Biological Solutions (cryogenic hardware manufacturing). Competitors in services include World Courier (a Cencora company), UPS Healthcare, Quick (a Kuehne+Nagel company), and Biocair. Cryoport completed the divestiture of its specialty courier CRYOPDP during the second quarter of fiscal year 2025. The company has never paid a cash dividend and carries convertible indebtedness.

Revenue model

Transactional and service-fee revenue from temperature-controlled logistics, biostorage, and bioservices sold directly to life science clients (Life Sciences Services segment), plus product sales of cryogenic freezers, dewars, and transport systems sold directly or through distributors (Life Sciences Products segment). No subscription or royalty model is disclosed in the filing.

Products and services

Cryoport Systems: temperature-controlled BioLogistics, BioServices, cryopreservation, cGMP storage, kit production, labeling, packaging, and commercial therapy fulfillment. CryoGene: long-term temperature-controlled biostorage and value-added services for preclinical and early-stage clinical programs. MVE Biological Solutions: cryogenic freezers, dewars, and transport systems for biological material storage and movement. Digital platform: Cryoportal Digital Logistics Management Platform (IoT monitoring, API integrations, Chain of Compliance data capture). IntegriCell and CryoVerse listed as additional platforms in development.

Customers and end markets

Biopharmaceutical companies and clinical research organizations operating in the cell and gene therapy market, spanning clinical development through commercial product launch. Allogeneic (off-the-shelf) therapies represent roughly one-third of the company's global clinical pipeline as of the FY2025 10-K filing dated 2026-03-05. No individual customer concentration figures are disclosed in the provided excerpts.

Value-chain role

End-to-end temperature-controlled supply chain intermediary sitting between biological material collection and patient delivery. Handles transport, storage, bioservices, packaging, digital tracking, and regulatory compliance for CGT and broader life sciences clients. Also an upstream equipment manufacturer via MVE Biological Solutions.

Geographic exposure

Operations span the United States (Brentwood, Tennessee; Irvine, California; Morris Plains, New Jersey; Houston, Texas; Ball Ground, Georgia; New Prague, Minnesota), Europe (Louvres, France; Liège, Belgium; Hoofddorp, Netherlands; Clermont-Ferrand, France), and Asia (Chengdu, China), as disclosed in the 10-K filed 2026-03-05.

Competitors

World Courier (a Cencora company), UPS Healthcare, Quick (a Kuehne+Nagel company), Biocair

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations Peers: Abbott Laboratories Butterfly Network Inc LeMaitre Vascular Inc NEVRO CORP Paragon 28, Inc. Procept Biorobotics Corp Treace Medical Concepts, Inc Transmedics Group Inc